Marksans Pharma Limited — Telmisartan Exporter Profile
Indian Pharmaceutical Exporter · #13 for Telmisartan · $1.4M export value · DGFT Verified
Marksans Pharma Limited is the #13 Indian exporter of Telmisartan with $1.4M in export value and 29 verified shipments. Marksans Pharma Limited holds a 0.0% market share in Telmisartan exports across 3 countries. The company exports 22 pharmaceutical products worth $125.0M across 11 therapeutic categories.
Marksans Pharma Limited — Telmisartan Export Profile: Buyers & Destinations
Where Does Marksans Pharma Limited Export Telmisartan?
| Country | Value | Shipments | Share |
|---|---|---|---|
| CANADA | $565.6K | 14 | 49.2% |
| GERMANY | $483.7K | 14 | 42.1% |
| MALTA | $100.0K | 2 | 8.7% |
Marksans Pharma Limited exports Telmisartan to 3 countries. The largest destination is CANADA accounting for 49.2% of Marksans Pharma Limited's Telmisartan shipments, followed by GERMANY (42.1%) and MALTA (8.7%). These destinations reflect Marksans Pharma Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Telmisartan from Marksans Pharma Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| TEVA CANADA LIMITED | CANADA | $565.6K | 14 |
| MERCKLE GMBH KREDITORENBUCHHALTUNG | GERMANY | $252.3K | 8 |
| MERCKLE GMBH | GERMANY | $181.4K | 5 |
| ACTAVIS LTD B16 BULEBEL INDUSTRIAL | MALTA | $100.0K | 2 |
| MERCKLE GMBHKREDITORENBUCHHALTUNG | GERMANY | $50.0K | 1 |
Marksans Pharma Limited supplies Telmisartan to 5 buyers globally. The largest buyer is TEVA CANADA LIMITED (CANADA), followed by MERCKLE GMBH KREDITORENBUCHHALTUNG (GERMANY) and MERCKLE GMBH (GERMANY). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Telmisartan Export Value and How Much Does Marksans Pharma Limited Contribute?
India exported $172.2M worth of Telmisartan through 11,086 shipments from 413 suppliers to 132 countries, serving 1,116 buyers globally. Marksans Pharma Limited contributes $1.4M to this total, accounting for 0.0% of India's Telmisartan exports. Marksans Pharma Limited ships Telmisartan to 3 countries through 5 buyers.
What Is the Average Shipment Value for Marksans Pharma Limited's Telmisartan Exports?
Marksans Pharma Limited's average Telmisartan shipment value is $50.0K per consignment, based on 29 shipments totaling $1.4M. The largest destination is CANADA (49.2% of Marksans Pharma Limited's Telmisartan exports).
How Does Marksans Pharma Limited Compare to Other Indian Telmisartan Exporters?
Marksans Pharma Limited ranks #13 among 413 Indian Telmisartan exporters with a 0.0% market share. The top 3 exporters are CIPLA LIMITED ($81.0M), INTAS PHARMACEUTICALS LIMITED ($15.5M), MYLAN LABORATORIES LIMITED ($12.0M). Marksans Pharma Limited processed 29 shipments to 3 destination countries.
What Telmisartan Formulations Does Marksans Pharma Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| PHARMACEUTICAL PRODUCTS - TEVA-TELMISARTAN 40 MG T. FASS F,VK,CA T, BATCH NO: 131701,131702,131703 MFG DT: DEC-2023 EXPNOS | $133.4K | 3 |
| PHARMACEUTICAL PRODUCTS - TEVA-TELMISARTAN 40 MG T. FASS F,VK,CA T, BATCH NO: 131700 MFG DT: DEC-2023 EXP DT: NOV-2025NOS | $122.6K | 3 |
| PHARMACEUTICAL PRODUCTS -TEVA-TELMISARTAN 40 MG T. FASS - F,VK,CA T - BATCH NO:131657,131688,131690,131691MFG DT: NOV-20NOS | $81.5K | 3 |
| PHARMACEUTICAL PRODUCTS : TELMISARTAN 8012.5MG T(EIMER) F,VK IN T Batch No: 131356 Mfg Dt: OCT-2023 Exp Dt: SEP-2026 (7 | $57.2K | 2 |
| PHARMACEUTICAL PRODUCTS : TELMISARTAN 80MG T FASS (TPW) F, VK, IN T ( Batch No:131604,131605 Mfg Dt: NOV-2023 Exp Dt: O | $56.1K | 3 |
| PHARMACEUTICAL ARTICLE / ODS / PRODUCT / ITEM : TELMISARTAN 20 | $50.0K | 1 |
| PHARMACEUTICAL ARTICLE / ODS / PRODUCT / ITEM -TEVA-TELMISARTAN80 12 5T. FASS FVKCA T Batch No: 131178 131179131180131182 Mfg Dt: AUG-20 | $50.0K | 1 |
| PHARMACEUTICAL ARTICLE / ODS / PRODUCT / ITEM : TELMISARTAN 60MG FT EU FASS F VK IN T BATCH NO :131385131384 MFG DT : OCT -2023 EXP DT | $50.0K | 1 |
| PHARMACEUTICAL ARTICLE / ODS / PRODUCT / ITEM : TELMISARTAN 80MG T FASS TPW F VK IN T BATCH NO : 130920 131368 MFG DT : JUL-2023 EXP DT : | $50.0K | 1 |
| PHARMACEUTICAL ARTICLE / ODS / PRODUCT / ITEM - TEVA-TELMISARTAN80 12 5T. FASS FVKCA T BATCH NO:131354 131355 MFG DT:OCT-2023 EXP DT:SEP- | $50.0K | 1 |
Marksans Pharma Limited exports 21 distinct Telmisartan formulations including tablets, capsules, syrups, and combination drugs. The top formulation is PHARMACEUTICAL PRODUCTS - TEVA-TELMISARTAN 40 MG T. FASS F,V with 3 shipments worth $133.4K.
Regulatory Requirements: Exporting Telmisartan to Key Markets
What Marksans Pharma Limited must comply with to export Telmisartan to its top destination countries
Canada — HC
Approval Process
ANDS (Abbreviated New Drug Submission) referencing Canadian Reference Product. Comparative bioavailability study required.
Timeline: 12–18 months
GMP & Export Requirements
Health Canada GMP (GUI-0001); Drug Establishment Licence (DEL) inspection
Drug Identification Number (DIN) for each product; Certificate of Pharmaceutical Product from CDSCO
Note: Subject to Good Import Practices and annual C.01.014.6 review.
Germany — BfArM/EMA
Approval Process
Marketing Authorisation via Decentralized or Mutual Recognition Procedure under EU Directive 2001/83/EC. CTD Module 1–5 dossier required.
Timeline: 12–18 months via Decentralized Procedure
GMP & Export Requirements
EU GMP (EudraLex Vol. 4); GMP certificate from EU competent authority; WHO Prequalification accepted as supporting evidence
Certificate of Pharmaceutical Product (CPP) from CDSCO; Written Confirmation for API export per EU requirements; EU FMD serialization mandatory
Note: Indian manufacturers must hold EU GMP certificate. EU Falsified Medicines Directive (FMD) serialization and tamper-evident packaging mandatory.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Marksans Pharma Limited Compare to Nearest Telmisartan Exporters?
Exporters ranked immediately above and below #13 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 11 | TORRENT PHARMACEUTICALS LTD | $3.7M | 98 | 7 | $37.7K |
| 12 | TEVAPHARM INDIA PRIVATE LIMITED | $3.3M | 93 | 3 | $35.3K |
| 13 | MARKSANS PHARMA LIMITED ★ | $1.4M | 29 | 3 | $50.0K |
| 10 | MEDIWIN PHARMACEUTICALS | $1.3M | 26 | 3 | $50.0K |
| 15 | PHARMAFABRIKON | $600.0K | 12 | 1 | $50.0K |
Marksans Pharma Limited ranks #13 among 413 Indian Telmisartan exporters. Average shipment value of $50.0K compared to the market average of $416.8K. The closest competitors by value are TORRENT PHARMACEUTICALS LTD and TEVAPHARM INDIA PRIVATE LIMITED.
Which Indian Ports Ship Telmisartan Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 1,766 | 15.9% |
| SAHAR AIR | 1,729 | 15.6% |
| DELHI AIR CARGO ACC (INDEL4) | 1,003 | 9.0% |
| NHAVA SHEVA SEA (INNSA1) | 755 | 6.8% |
| DELHI AIR | 623 | 5.6% |
| AHEMDABAD AIR | 402 | 3.6% |
| Bombay Air | 396 | 3.6% |
| JNPT | 377 | 3.4% |
What Other Cardiovascular Products Does Marksans Pharma Limited Export?
Marksans Pharma Limited also exports these cardiovascular products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Marksans Pharma Limited's Telmisartan Exports
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Marksans Pharma. The ongoing Israel-Iran tensions have led to increased security risks in the Red Sea, a crucial maritime route for trade between Asia and Europe. Major shipping lines have introduced an 'Emergency Risk Surcharge' ranging from $250 to $500 per TEU for cargo transiting the Bab-el-Mandeb Strait, effective February 2025. This surcharge elevates shipping costs, potentially impacting the competitiveness of Indian pharmaceutical exports to European and US East Coast markets. (sgeexport.com)
Conversely, the India–European Union Free Trade Agreement (FTA), concluded in January 2026, offers a silver lining. The FTA eliminates tariffs on Indian pharmaceuticals, APIs, vaccines, and medical devices, providing immediate cost relief and enhancing market access for Indian exporters. This development positions Marksans Pharma favorably to increase its footprint in the European market, leveraging its existing regulatory approvals and manufacturing capabilities. (en.wikipedia.org)
Marksans Pharma Limited — Regulatory Compliance & Quality Standards
Maintaining stringent quality standards is paramount for pharmaceutical exporters. Marksans Pharma has demonstrated a strong commitment to regulatory compliance. In November 2025, the company's Goa facility underwent a current Good Manufacturing Practice (cGMP) inspection by the US FDA, concluding with zero Form 483 observations. This outcome reflects Marksans' dedication to adhering to international quality standards and regulatory requirements. (capitalmarket.com)
Furthermore, the company's subsidiaries have achieved significant regulatory milestones. Time-Cap Laboratories Inc., Marksans' US subsidiary, received an Establishment Inspection Report (EIR) from the US FDA for its New York-based facility in June 2025, following an inspection that resulted in only one observation with no data integrity issues. Such achievements bolster Marksans' reputation as a reliable and compliant pharmaceutical manufacturer. (business-standard.com)
About Marksans Pharma Limited
Marksans Pharma Limited exports 22 products worth $125.0M. Beyond Telmisartan, top products include Ibuprofen, Amino, Gabapentin, Acetaminophen, Loratadine. View the complete Marksans Pharma Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Telmisartan — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Telmisartan shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Marksans Pharma Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 30 individual customs records matching Marksans Pharma Limited exporting Telmisartan, covering 21 formulations to 3 countries via 5 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 132+ countries, 1,116+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Telmisartan Export Data from Marksans Pharma Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Marksans Pharma Limited's Telmisartan exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Marksans Pharma Limited
Full Company Profile →
22 products · $125.0M total trade · 11 categories
Telmisartan Stats
Company Overview
Top Products by Marksans Pharma Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Marksans Pharma Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Telmisartan. For current shipment-level data, contact TransData Nexus.